French Pharma Stock News

ABC arbitrage (ENXTPA:ABCA) posts higher first half revenue with solid EPS contribution ABC arbitrage (ENXTPA:ABCA) has reported first half FY 2025 revenue of €36.6 million with basic EPS of €0.30, setting the tone for a set of results anchored by higher trailing 12 month revenue of €65.1 million and EPS of €0.60. Over recent periods, revenue has moved from €22.9 million in the first half of 2024 to €28.6 million in the second half and now €36.6 million in the first half of 2025, while basic...

ABIVAX Société Anonyme (ENXTPA:ABVX) has reported FY 2025 third quarter revenue of €0.639 million and a basic EPS loss of €2.10, while trailing twelve month figures show revenue of €5.311 million and a basic EPS loss of €4.46. Over recent quarters, revenue has moved from €1.351 million in Q3 2024 to €0.97 million in Q1 2025 and €1.047 million in Q2 2025, with basic EPS losses of €0.87, €0.83 and €0.76 across those same periods, and a trailing net loss of €293.52 million anchoring the story...

Earnings and dividend proposal put Rubis in focus Rubis (ENXTPA:RUI) has drawn fresh attention after reporting full year 2025 results, showing slightly lower sales and net income, while at the same time proposing a higher dividend per share for shareholders. See our latest analysis for Rubis. The share price reaction around the earnings and dividend news has been mixed, with a 1-day share price return of 1.09% but a 30-day share price return decline of 7.45%, while the 1-year total...

Société Générale Société anonyme (ENXTPA:GLE) has completed a share buyback, repurchasing 20,964,286 shares, about 2.78% of its capital, for €1,467.83 million, a move that directly affects remaining shareholders. See our latest analysis for Société Générale Société anonyme. Despite the €1.4b buyback and recent bond issue, the share price has been under pressure in the short term, with a 1 month share price return decline of 13.88% and a year to date share price return decline of 9.36%. At the...

With no specific headline event driving attention today, Danone (ENXTPA:BN) is drawing interest as investors reassess its recent share performance and fundamentals, including revenue of €27.3b and net income of €1.8b. See our latest analysis for Danone. At a share price of €68.32, Danone’s recent trend shows weaker short term momentum, with a 30 day share price return of 7.17% and a 90 day return of 11.13%. The 5 year total shareholder return of 37.25% points to a steadier long run...

Elis (ENXTPA:ELIS) has priced €600 million in senior unsecured notes under its EMTN programme. The funds are intended for debt refinancing and a new share buyback program. The placement was strongly oversubscribed, indicating solid demand from investors. Elis, a provider of textile, hygiene and facility services, operates in sectors where clients often rely on long term outsourcing contracts, from hospitality and healthcare to industry. Recent years have kept attention on operational...

Why Carrefour stock is drawing attention now Carrefour (ENXTPA:CA) is back on many investors’ screens after recent share price moves, with the stock showing a mix of shorter term weakness and longer term strength across different time frames. See our latest analysis for Carrefour. The recent pullback, including a 1-day share price return of a 1.57% decline and a 7-day share price return of a 4.40% decline, sits against a 1-year total shareholder return of 26.84%. This suggests momentum has...

Why Airbus stock is back on investors’ radar Airbus (ENXTPA:AIR) has caught investor attention after a period where the share price shows mixed recent returns, including a 3.4% gain over the past day and a decline over the past month. See our latest analysis for Airbus. The recent 1 day share price return of 3.41% comes after a weaker spell, with the 30 day share price return of 12.30% and year to date share price return of 18.31%. In contrast, the 5 year total shareholder return of 82.84%...

Vivendi earnings and dividend move into focus Vivendi (ENXTPA:VIV) has just reported full year 2025 earnings alongside a proposed ordinary dividend of €0.04 per share, bringing both profitability and cash distributions onto investors’ radar. See our latest analysis for Vivendi. Despite reporting a move from a net loss to net income and putting a cash dividend back on the table, Vivendi’s 30 day share price return of 23.16% and 1 year total shareholder return of 38.66% both remain weak. This...

Traffic uptick puts Aeroports de Paris in focus Aeroports de Paris (ENXTPA:ADP) has come into focus after reporting group traffic of 26,664,481 passengers for February 2026, up 5.0%, and 56,169,552 year to date, up 2.9%, indicating a pickup in passenger volumes. See our latest analysis for Aeroports de Paris. The February traffic update arrives after a mixed share price run, with Aeroports de Paris posting a 1 day share price return of 0.58% but a 30 day share price return decline of 12.56%...

Sanofi has entered a global licensing agreement with Kali Therapeutics for KT501, a tri specific T cell engager for autoimmune diseases currently in clinical trials for rheumatoid arthritis. Dupixent has received regulatory approval in Japan for moderate to severe bullous pemphigoid, a rare and serious dermatologic condition with limited treatment options. These developments expand Sanofi's immunology and rare disease franchises, highlighting progress in first in class and best in class...

SEB (ENXTPA:SK) has been removed from the FTSE All-World Index, a change that can influence investor flows as index-tracking funds adjust positions and reassess their exposure to the French home appliance group. See our latest analysis for SEB. SEB's removal from the FTSE All-World Index comes after a sharp 16.74% 1 month share price return decline and a 49.74% 1 year total shareholder return loss, pointing to fading momentum as index related selling meets already weak sentiment. If this kind...

Investors may be wondering whether Capgemini at €98.24 is starting to look interesting again, or if the current price still feels rich for the risk involved. The stock has fallen 6.5% over the last week, 6.0% over the last month, and is down 30.2% year to date and 31.4% over the past year, which will catch the eye of anyone watching for potential value or a further shift in risk sentiment. Recent coverage has focused on how sustained share price weakness has put more attention on...

Investors may be wondering whether L'Oréal's current share price reflects its true worth, or if the market is mispricing this beauty giant. The stock last closed at €344.90, with a 14.0% decline over the past 30 days and a smaller 2.0% pullback in the last week. Over a 1 year period the return sits at 0.6%, and over 5 years the return stands at 13.6%. Recent coverage around L'Oréal has focused on its position as a global consumer brand and how investor sentiment has been adjusting in...

Wondering whether STMicroelectronics is offering good value at its current price, or if the recent run has already done the heavy lifting for you? The stock closed at €27.00, with a 7 day return of 8.1% decline and a 30 day return of 5.4% decline, but is still up 15.2% year to date and 21.9% over the last year, while the 3 year and 5 year returns sit at 39.3% decline and 11.7% decline. Recent headlines around STMicroelectronics have focused on its role in the broader semiconductor supply...

Eurofins Scientific and recent share performance Eurofins Scientific (ENXTPA:ERF) has drawn investor attention after recent share moves, including a roughly 10% decline over the past month. This has prompted closer inspection of its fundamentals and valuation signals. See our latest analysis for Eurofins Scientific. Despite the recent 10% 30 day share price decline and a modest year to date share price fall of 2%, Eurofins Scientific’s 1 year total shareholder return of 21.48% points to...

Recent share performance and valuation context Renault (ENXTPA:RNO) has been on many watchlists after a weak share performance in the past year, with the stock down 41.1% on a total return basis and more than 20% over the past 3 months. See our latest analysis for Renault. The share price, now at €27.64, has seen momentum fade over recent months, with a 30 day share price return of a 14.6% decline and a 1 year total shareholder return of a 41.1% loss. If Renault’s recent slide has you...

Index inclusion puts ABIVAX Société Anonyme (ENXTPA:ABVX) on more investor radars ABIVAX Société Anonyme (ENXTPA:ABVX) has been added to the FTSE All-World Index (USD), an index change that can shift attention from active stock pickers to index trackers that are adjusting their biotech allocations. See our latest analysis for ABIVAX Société Anonyme. The latest index inclusion comes as ABIVAX Société Anonyme trades at €109.4, with a 3.21% 1 day share price return and a 1 year total shareholder...

Context on Elis and recent share performance Elis (ENXTPA:ELIS) has drawn attention after recent share price moves, with the stock showing a 2.4% decline over the past day and a 6.9% decline over the past week. Those short term moves contrast with its longer record. Over the past year, the total return is 12.9%, and the past 3 years and 5 years show very large gains on a total return basis. See our latest analysis for Elis. The recent 13.5% 1 month share price decline to €23.82 comes after a...

Capgemini (ENXTPA:CAP) has remained in focus after a stretch of weaker share performance, with the stock down about 5.7% over the past month and roughly 31.8% over the past 3 months. See our latest analysis for Capgemini. Beyond the recent setbacks, Capgemini’s share price return has been weak both in the short term and over longer horizons, with the 1 year total shareholder return decline of 30.95% highlighting pressure on sentiment despite its €98.58 share price today. If you are...

Hermès International has filed its 2025 Universal Registration Document with the French Financial Markets Authority, making its latest annual activity report, consolidated financial statements, sustainability information, and share buyback programme details available to the public. This comprehensive filing gives investors a single source to review Hermès’ financial position, non-financial commitments, and capital allocation approach, including how buybacks fit alongside its long-term brand...

If you are wondering whether ABIVAX Société Anonyme is priced attractively after its huge run, or if the current share price already reflects the story, this article breaks down what the numbers say about value. The stock last closed at €109.40, with a 7 day return of 8.1%, a 30 day return showing a 0.9% decline, a year to date return showing a 4.9% decline, and a 1 year gain that is very large compared to where it started. Recent news coverage has focused on ABIVAX Société Anonyme as a high...

Event driven interest in GL Events GL Events (ENXTPA:GLO) is drawing fresh attention as its fashion division brings the first Denim Première Vision edition to Tokyo, alongside Tranoï Tokyo, aiming to connect global denim players with Asian markets. See our latest analysis for GL Events. At a share price of €32.05, GL Events has a 1 day share price return of 1.42% and a 90 day share price return of 7.73%. The 1 year total shareholder return of 60.5% contrasts with a 5.6% 30 day share price...

Dividend increase and weaker earnings put Compagnie de l'Odet (ENXTPA:ODET) in focus Compagnie de l'Odet (ENXTPA:ODET) has drawn attention after full year 2025 results showed sales of €2,924 million and net income of €218 million, alongside a proposed 9% higher dividend of €4.80 per share. See our latest analysis for Compagnie de l'Odet. The dividend and earnings announcement comes after a mixed price pattern, with a 7 day share price return of 8.7% following weaker recent momentum, including...